Actively Recruiting
HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
Led by Montefiore Medical Center · Updated on 2025-07-23
40
Participants Needed
1
Research Sites
310 weeks
Total Duration
On this page
Sponsors
M
Montefiore Medical Center
Lead Sponsor
H
HepQuant, LLC
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a pilot and feasibility study assessing the role of quantitative multiparametric MRI and blood-based biomarkers for the measurement of liver function in patients receiving radiation therapy for liver cancer, including hepatocellular carcinoma (HCC), cholangiocarcinoma, or liver metastases regardless of primary histology, that are undergoing photon radiation either in the de-novo or re-irradiation setting. The goal of this study is to prospectively evaluate the feasibility of using quantitative multiparametric MRI to monitor liver function at baseline and following liver radiation therapy.
CONDITIONS
Official Title
HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 18 years
- Psychological ability and general health to provide informed consent and complete study requirements and follow-up
- Patient provides study-specific informed consent before joining
- Diagnosed with hepatocellular carcinoma, cholangiocarcinoma, or liver metastases of any primary histology
- Prior radiation therapy allowed with no limit on number of courses
- Any number and size of tumor lesions targeted
- Prior liver resection, chemoembolization, or ablation allowed without restrictions
- Prior chemotherapy, immunotherapy, or targeted therapy allowed
- Concurrent enrollment in other prospective registries or treatment trials allowed
You will not qualify if you...
- Pregnant or breastfeeding females
- History of claustrophobia affecting ability to complete MRI
- Contraindications to MRI such as ferromagnetic material, metal fragments, implanted electronic devices, or metal tattoos
- Unable to undergo MRI due to equipment size or weight limits
- Unable to lie still or hold breath during MRI
- For HepQuant DuO test: allergy to human serum albumin or test ingredients
- History of extensive small intestine resection or severe gastroparesis
- Use of non-selective beta blockers, ACE inhibitors, or ARBs unwilling or unable to delay dose on test day
- Unwilling or unable to fast for at least 5 hours before testing
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Montefiore Medical Center
The Bronx, New York, United States, 10467
Actively Recruiting
Research Team
R
Rafi Kabarriti, MD
CONTACT
R
Rikin Gandhi
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here